In American football, there is a well-known phrase: “Games are won and lost in the trenches.” This expression reminds us that victory rarely depends only on the most visible players. Instead, it is often determined by those who work under the harshest, most demanding, and least recognized conditions. Long before the final score appears, the outcome is already being shaped in those invisible battles.
In cancer, something very similar occurs.
The decisive battlefield is not limited to operating rooms, laboratories, or hospitals. It exists within the tumor microenvironment: a microscopic ecosystem composed of cancer cells, immune cells, blood vessels, metabolites, and signaling molecules. This complex environment ultimately determines whether the immune system succeeds in controlling the disease or gradually loses its ability to respond. Understanding this hidden battlefield is essential to explain why the same treatment may be highly effective in one patient and ineffective in another.
Under normal conditions, the body relies on a highly efficient immune surveillance system. Immune cells continuously patrol tissues in search of abnormal, mutated, or potentially dangerous cells. When such cells are detected, they are usually eliminated before they can cause harm. Cancer progression, however, depends largely on the failure of this surveillance. To survive and expand, tumors must develop strategies to evade immune recognition, and one of their most powerful tools is metabolic reprogramming. This adaptation not only supports rapid growth, but also actively weakens immune defenses.
Tumors further suppress immunity by recruiting immunosuppressive cells, such as myeloid-derived suppressor cells, regulatory T cells, and tumor-associated macrophages. In parallel, they exploit immune checkpoint pathways, activating receptors like PD-1, CTLA-4, TIM-3, and LAG-3, which function as molecular brakes. Although checkpoint inhibitors have transformed cancer therapy, they address only part of the problem. Beneath these signaling pathways lies a deeper layer of control: metabolism.
Cancer Metabolism and the Warburg Effect
Unlike most healthy cells, cancer cells produce energy in an unusual way. Normally, cells rely on oxygen and mitochondria to convert glucose into energy through cellular respiration, an efficient process. Cancer cells, however, often favor a different route.
Even when oxygen is available, they preferentially convert glucose into lactate. This phenomenon, known as the Warburg Effect, was described by Otto Warburg in 1924. In simple terms, healthy cells use a modern, efficient engine, while cancer cells rely on a faster but less efficient one that consumes more fuel.
Although this pathway produces less energy per glucose molecule, it offers important advantages. It enables rapid energy production, supports continuous proliferation, generates molecular building blocks for DNA, proteins, and membranes, and produces large amounts of lactate. It also allows tumors to adapt to hypoxia, nutrient scarcity, and metabolic stress. In this way, metabolism becomes both an offensive and defensive weapon.
Acidity and Immune Suppression
As tumors convert glucose into lactate, they generate large quantities of acid. This acid is expelled into surrounding tissues, leading to a persistent decrease in pH. While cancer cells protect their internal environment, they create an external space that is hostile to immune cells.
Low pH profoundly affects immune function. Interferon gamma, a key cytokine for T-cell activation and tumor elimination, is especially sensitive to acidity. In acidic conditions, IFN-γ production decreases, T-cell proliferation slows, cytotoxic activity weakens, and cell survival declines. As acidity increases, immune cells progressively lose their functional capacity.
Experimental studies have shown that reducing lactate production can restore immune activity and slow tumor growth. This confirms that acidity is not merely a metabolic byproduct, but a strategic weapon used by tumors to weaken immune defenses.
Figure 1. Tumor metabolic reprogramming driven by the Warburg effect, where enhanced glucose-to-lactate conversion promotes cellular adaptation and acidifies the microenvironment. This acidic condition impairs immune function, highlighting pH regulation as a potential strategy to support therapeutic response.
Targeting Tumor Acidity and Metabolism
Given the central role of acidity, researchers have explored methods to neutralize it. Sodium bicarbonate has shown buffering effects in animal models, improving responses to immunotherapy, but its clinical use is limited by toxicity at high doses.
Proton pump inhibitors, such as pantoprazole, have emerged as promising alternatives. These drugs can increase tumor pH, reduce acidity, and promote antitumor immune responses. Originally developed for gastric disorders, they are now being reevaluated as metabolic modulators in oncology.
Other strategies, including glycolysis inhibitors like 3-bromopyruvate and targets such as LDH-A, have demonstrated potential, particularly when applied locally. At the same time, amino acid metabolism, involving pathways such as tryptophan–IDO and asparagine regulation, plays a crucial role in shaping immune responses.
However, targeting metabolism requires balance. Immune cells also depend on glucose and nutrients to function. Excessive metabolic inhibition may harm both the tumor and the immune system. Effective therapy therefore requires precision, personalization, and careful modulation rather than complete blockade.
Conclusion
The acidic tumor microenvironment is not a biological accident. It is a carefully constructed defense system developed by cancer. Through metabolic reprogramming and pH regulation, tumors create conditions that suppress immune surveillance and promote survival.
Understanding how metabolism, acidity, and immunity interact opens new possibilities for enhancing immunotherapy. Metabolic checkpoints are likely to become central targets in the next generation of cancer treatments.
In these microscopic trenches, where cells compete under extreme conditions, the future of oncology is being defined.
Main reference:
Williams, J. R. (2019). The immunotherapy revolution the immunotherapy revolution: The best New Hope for saving cancer patients’ lives. Independently Published.
